logo
Share SHARE
FONT-SIZE Plus   Neg

Delcath Systems' Hepatic CHEMOSAT Delivery System Used First To Treat Patient

Specialty pharmaceutical company Delcath Systems Inc (DCTH) Friday revealed that the European Institute of Oncology, a premier cancer treatment and research center in Milan has performed the first treatment using the second generation hemofiltration cartridge of the Company's proprietary Hepatic CHEMOSAT Delivery System.

The company stated that a patient was treated for inoperable liver-dominant metastases from ocular melanoma, a case that represents the first use of the second generation hemofiltration cartridge in a clinical setting.

"We are pleased to finally be able to provide the second generation CHEMOSAT system to our early launch centers in Europe," said Eamonn P. Hobbs, President and CEO of Delcath Systems. "Now that we are beginning to treat patients with the new system, we are confident that efficiency data we've seen in our in vivo studies will be validated in actual clinical use. We are also pleased that the team at the IEO is the first to begin exploring the benefits of the new system, and look forward to working with them and other early launch centers to establish the benefits of this system for patients with cancers in the liver."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
HSBC is reportedly laying off about 100 of its senior investment bankers worldwide, as the banking giant strives to curb operating costs. According to reports, the London-headquartered bank will eliminate managing director and director level employees at the Global Banking and Markets division, as... Samsung Electronics Co., Ltd. (SMSN.L, SSNNF.OB, SSNLF.OB) will reportedly blame faulty batteries for last year's Galaxy Note 7 fiasco. According to a Wall Street Journal report, Samsung's investigation of Galaxy Note 7 smartphones found that some batteries were irregularly sized while others had... Federal investigators have closed their probe of a fatal crash that involved a Tesla Motors Inc. car eight months ago. The regulators said they have found no safety defects in the vehicle's automated driving system and that Tesla's Autopilot-enabled vehicles did not need to be recalled.
comments powered by Disqus
Follow RTT